Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.44 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.40 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422695 | 0.98 | SLC2A1 (0.58) | SLC2A1RAB9ACHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL11535429 | 0.81 | SLC2A1 (0.55) | SLC2A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL1735242 | 0.79 | SLC2A1 (0.58) | SLC2A1RAB9ACHRM2CHRM1CHRM3 | |
| SCHEMBL7061665 | 0.79 | SLC2A1 (0.56) | SLC2A1CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL14566171 | 0.79 | RAB9A (0.59) | RAB9AKDM4ETP53TSHRPOLB | |
| SCHEMBL5356846 | 0.76 | SLC2A1 (0.54) | SLC2A1ALDH1A1LMNANPSR1 | |
| SCHEMBL12749956 | 0.76 | SLC2A1 (0.46) | SLC2A1CHRM2CHRM3KDM4EALDH1A1 | |
| SCHEMBL3883354 | 0.76 | CA12 (0.52) | RAB9AKDM4ETP53TSHRPOLB | |
| SCHEMBL3838326 | 0.76 | SLC2A1 (0.53) | SLC2A1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL11675550 | 0.75 | MAPT (0.49) | SLC2A1RAB9ACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4553161-B1 | ANTIBIOTIC-FREE PLASMID PRODUCTION SYSTEM AND USE THEREOF | YUNZHOU BIOSCIENCES GUANGZHOU CO LTD (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122029283-A | Antibiotic-free property particle production system and application thereof | 云舟生物科技(广州)股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | UNIV MUENCHEN TECH (DE) | 2026-01-22 | — | — | US | claimed |
| EP-4651910-A1 | DUAL LABELLED COMPOUNDS TARGETING THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2025-11-26 | — | — | EP | claimed |
| EP-4642489-A1 | CONJUGATE AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-11-05 | — | — | EP | claimed |
| WO-2025202114-A1 | RADIOSENSITISING PEPTIDE COMPLEX | GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE (FR) | 2025-10-02 | — | — | WO | claimed |
| EP-4624225-A1 | LINEAR MOTOR WITH CAPACITIVE POWER TRANSFER | ABB Schweiz AG (CH) | 2025-10-01 | — | — | EP | claimed |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GMBH (NL) | 2025-09-23 | — | — | US | claimed |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2025-09-18 | — | — | US | claimed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | claimed |
| CN-112965374-B | Method for disassembling and scheduling in consideration of random demand and operation time under resource constraint | 郑州轻工业大学 | 2022-11-01 | — | — | CN | claimed |
| WO-2022171869-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-18 | — | — | WO | claimed |
| WO-2022171901-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | Technische Universität München (DE) | 2022-08-18 | — | — | WO | claimed |
| EP-4043041-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-17 | — | — | EP | claimed |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2022-04-21 | — | — | US | claimed |
| CN-114267798-A | One-step method for preparing amidino FAPBI in air at medium and low temperature3Method and application of perovskite solar cell | 西北工业大学 | 2022-04-01 | — | — | CN | claimed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | claimed |
| CN-107646391-B | Method for changing color of pepper fruits and increasing content of lycopene in pepper fruits | 黄淮学院 | 2020-08-21 | — | — | CN | claimed |
| US-4159903-A | AMINE BIOINDUCING AGENT ADMINISTERED TO GUAYULE PLANTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1979-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | HNRNPF, ANXA3, SLC67A1 | CHRM2 4081/4885CHRM1 3096/4885CHRM3 3523/4885 |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | FOLH1, SLC19A1, KLK3 | CHRM2 953/4885CHRM1 1000/4885CHRM3 1354/4885 |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | CXCR4, CXCR1, CXCR3 | CHRM2 882/4885CHRM1 342/4885CHRM3 657/4885 |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | FOLH1, FOLR1, KLK3 | CHRM2 4680/4885CHRM1 4380/4885CHRM3 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.